Skip to main content
SpringerLink
Log in

Cannabinoids in appetite and obesity

  • Chapter
Cannabinoids as Therapeutics

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel EL (1975) Cannabis: effects on hunger and thirst. Behav Biol 15: 255–281

    Article  PubMed  Google Scholar 

  2. Bonney RC (2002) Obesity: sizing up the market. Scrip Reports, PJB Publications, Richmond

    Google Scholar 

  3. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U (2003) Endogenous cannabinoid system as a modulator of food intake. Int J Obesity and Related Metabolic Disorders: J International Association for the Study of Obesity 27: 289–301

    Article  Google Scholar 

  4. Abel EL (1971) Effects of marihuana on the solution of anagrams, memory and appetite. Nature 231: 260–261

    PubMed  Google Scholar 

  5. Mattes RD, Engelman K, Shaw LM, Elsohly MA (1994) Cannabinoids and appetite stimulation. Pharmacol Biochem Behav 49: 187–195

    Article  PubMed  Google Scholar 

  6. Gagnon M, Elie R (1975) Effects of marijuana and D-amphetamine on the appetite, food consumption and various cardio-respiratory variables in man. Union Med Can 104: 914–921

    PubMed  Google Scholar 

  7. Foltin RW, Fischman MW, Byrne MF (1988) Effects of smoked marijuana on food intake and body weight of humans living in residential laboratory. Appetite 11: 1–14

    Article  Google Scholar 

  8. Hollister L (1971) Hunger and appetite after single doses of marihuana, alcohol, and dextroam-phetamine. Clin Pharmacol Ther 12: 44–49

    PubMed  Google Scholar 

  9. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG (1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40: 695–700

    Article  PubMed  Google Scholar 

  10. Volicer L, Stelly M, Morris J, McLaughlin JVBJ (1997) Effects of dronabinol on anorexia and disturbed behavior in patient with Alzeihmer’s disease. Int J Geriat Psychiat 12: 913–919

    Article  Google Scholar 

  11. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV (1995) Dronabinol as a Treatment for Anorexia Associated with Weight Loss in Patients with AIDS. J Pain Symptom Manage 10: 89–97

    Article  PubMed  Google Scholar 

  12. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF (1997) Long-Term Efficacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-Associated Anorexia. JPain Symptom Manage 14: 7–14

    Article  Google Scholar 

  13. Timpone J, Wright D, Li N, Egorin M, Enama M, Mayers J, Galetto G (1999) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. In: G Nahas, K Sutin, D Harvey, S Agurel (eds): Marihuana and medicine. Humana Press, Totowa, New Jersey, 701–706

    Google Scholar 

  14. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, F. Barth and M. Rinaldi-Carmona Kosel B, Aberg JA et al. (2003) Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection: A Randomized, Placebo-Controlled Clinical Trial. Ann Intern Med 139: 258–266

    PubMed  Google Scholar 

  15. Williams CM, Rogers PJ, Kirkham TC (1998) Hyperphagia in pre-fed rats following oral [delta]9-THC. Physiol Behav 65: 343–346

    Article  PubMed  Google Scholar 

  16. Koch JE (2001) [Delta]9-THC stimulates food intake in Lewis rats: effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 68: 539–543

    Article  PubMed  Google Scholar 

  17. Miller CC, Murray TF, Freeman KG, Edwards GL (2004) Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain. Physiol Behav 80: 611–616

    Article  PubMed  Google Scholar 

  18. Giuliani D, Ottani A, Ferrari F (2000) Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats. Eur J Pharmacol 391: 275–279

    Article  PubMed  Google Scholar 

  19. Graceffo TJ, Robinson JK (1998) Delta-9 tetrahydrocannabinol (THC) fails to stimulate sonsumption of a highly palatable food in the rat. Life Sci 62: L85–L88

    Article  Google Scholar 

  20. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 143: 315–317

    Article  PubMed  Google Scholar 

  21. Hao S, Avraham Y, Mechoulam R, Berry EM (2000) Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392: 147–156

    Article  PubMed  Google Scholar 

  22. Jamshidi N, Taylor DA (2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Brit J Pharmacol 134: 1151–1154

    Article  Google Scholar 

  23. Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Brit J Pharmacol 136: 550–557

    Article  Google Scholar 

  24. Gallate JE, Saharov T, Mallet PE, McGregor IS (1999) Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. Eur J Pharmacol 370: 233–240

    Article  PubMed  Google Scholar 

  25. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R (2001) Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419: 207–214

    Article  PubMed  Google Scholar 

  26. Fride E, Foox A, Rosenberg E, Faigenboim M, Cohen V, Barda L, Blau H, Mechoulam R (2003) Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. Eur J Pharmacol 461: 27–34

    Article  PubMed  Google Scholar 

  27. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240–244

    Article  PubMed  Google Scholar 

  28. Williams CM, Kirkham TC (2002) Reversal of [Delta]9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71: 333–340

    Article  PubMed  Google Scholar 

  29. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132: 104–106

    Article  PubMed  Google Scholar 

  30. Simiand J, Keane M, Keane PE, Soubrie P (1998) SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavi Pharmacol 9: 179–181

    Google Scholar 

  31. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63: L113–L117

    Article  Google Scholar 

  32. Freedland CS, Sharpe AL, Samson HH, Porrino LJ (2001) Effects of SR141716A on ethanol and sucrose self-administration. Alcohol Clin Exp Res 25: 277–282

    Article  PubMed  Google Scholar 

  33. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284: R345–R353

    PubMed  Google Scholar 

  34. Hildebrandt AL, Kelly-Sullivan DM, Black SC (2003) Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462: 125–132

    Article  PubMed  Google Scholar 

  35. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822–825

    Article  PubMed  Google Scholar 

  36. Armone M, Millet L, Maffrand JP, Soubrie P (2004) Rimonabant reduces weight gain in obese zucker rats by regulating hyperphagia and activating fatty acid oxidation. In: Abstracts of the 13th European Congress on Obesity (ECO), Prague, Czech Republic, 26–29 May 2004. Int J Obes Relat Metab Disord 28(Suppl. 1): 77

    Google Scholar 

  37. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Pério A, Poncelet M, Maruani J, Arnone M, Finance O et al. (2004) SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-Cannabinoids in appetite and obesity 4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 310: 905–914

    Article  PubMed  Google Scholar 

  38. Fong MT, Goulet M, Hagman W, Plummer C, Finke P, Mills S, Shah S, Truong Q., Shen C, Lao, J, Van der Ploeg L (2003) Biological and pharmacological activity of new CBIR inverse agonist, 2003 Symposium on the Cannabinoids p 1, International Cannabinoid Research Society, Burlington, Vermont

    Google Scholar 

  39. Smith R.A, O’Connor SJ, Wirtz SN, Wong WC, Choi S, Kluender HC, Su N, Wang G, Achebe F, Ying S (2003) Imidazole-4-carboxamide derivatives, preparation and use thereof for the treatment of obesity. International Patent Application WO 03/040107

    Google Scholar 

  40. Le Fur G, Arnone M, Rinaldi-Carmona M, Barth F, Heshmati H (2001) SR141716, a selective antagonist of CB1 receptors and obesity, 2001 Symposium on the Cannabinoids p.101 International Cannabinoid Research Society, Burlington, Vermont

    Google Scholar 

  41. Jensen M, Abu-Lebdeh H, Geohas J, Brazg R, Block M, Noveck R, Free R (2004) The selective CB1 receptor antagonist rimonabant reduces body weight and waist circumference in obese subjects. Int J Obesity 28(Suppl. 1): Abst T5:02-001

    Google Scholar 

  42. Dale L, Anthenelli R, Després JP, Golay A, Sjostrom L (2004) Effects of rimonabant in the reduction of major cardiovascular risk factors: results from the STRATUS-US trial (Smoking cessation in smokers motivated to quit) and the RIO-LIPIDS trial (Weight reduction and metabolic effects in overweight/obese patients with dyslipidemia). American College of Cardiology Annual Scientific Sessions, Presentation 409-1, March 7–10, 2004, New Orleans

    Google Scholar 

  43. Houri M, Pratley RE (2005) Rimonabant: a novel treatment for obesity and the metabolic syndrome. Curr Diab Rep 5: 43–44

    Google Scholar 

  44. Van Gaal L (2004) RIO-EUROPE: a randomized double-blind study of weight reducing effect and safety of rimonabant in obese patients with or without comorbidities, European Society of Cardiology Congress, Presentation 106, August 28–September 1, 2004, Munich

    Google Scholar 

  45. Schwartz MW, Woods SC, Porte D, Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404: 661–671

    PubMed  Google Scholar 

  46. Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra, Le Fur G (1998) SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. The. J Pharmacol Exp Ther 284: 644–650

    PubMed  Google Scholar 

  47. Poncelet M, Maruani J, Calassi R, Soubrie P (2003) Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice. Neurosci Lett 343: 216–218

    PubMed  Google Scholar 

  48. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P (2003) Hypersensitization of the Orexin 1 receptor by the CB 1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. The. J Biol Chem 278: 23731–23737

    Article  PubMed  Google Scholar 

  49. Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004) Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145:3224–3231

    Article  PubMed  Google Scholar 

  50. Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P (2002) SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavi Pharmacol 13: 451–463

    Google Scholar 

  51. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carbox-amide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. The. J Pharmacol Exp Ther 306: 93–102

    Article  PubMed  Google Scholar 

  52. Deroche-Gamonet V, Le Moal M, Piazza PV, Soubrie P (2001) SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats. Psychopharmacologia 157: 254–259

    Article  Google Scholar 

  53. Kirkham TC, Williams CM (2001) Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacologia 153: 267–270

    Article  Google Scholar 

  54. Chen RZ, Huang RR, Shen CP, MacNeil DJ, Fong TM (2004) Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. Brain Res 999: 227–230

    Article  PubMed  Google Scholar 

  55. Croci T, Landi M, Manara L, Rinaldi-Carmona M (2002) Body weight curbing and respiratory quotient lowering effect of the cannabinoid CB1 receptor antagonist SR141716 (Rimonabant) in rats. IUPHAR Meeting, July 7–12, 2002, San Fransico, CA

    Google Scholar 

  56. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The. J Clin Invest 112: 423–431

    Article  PubMed  Google Scholar 

  57. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908–914

    Article  PubMed  Google Scholar 

  58. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F (2002) A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding. JNeurosci 22: 9612–9617

    Google Scholar 

  59. Cleland JGF, Gosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP (2004) Clinical trials update and cumulative meta-analyses from the American College of Cardiology. WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy i heart failure. Eur J Heart Fail 6: 501–508

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sanofi-aventis, 371, rue du Professeur Joseph Blayac, 34184, Montpellier Cedex 04, France

    Francis Barth & Murielle Rinaldi-Carmona

Authors
  1. Francis Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murielle Rinaldi-Carmona
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Faculty, Hebrew University, Ein Kerem, Jerusalem, 91010, Israel

    Raphael Mechoulam

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Barth, F., Rinaldi-Carmona, M. (2005). Cannabinoids in appetite and obesity. In: Mechoulam, R. (eds) Cannabinoids as Therapeutics. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7358-X_13

Download citation

Publish with us

Policies and ethics

Search

Navigation